Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review

Bimekizumab is a biologic targeting interleukin (IL)-17A/17F, approved by the Food and Drug Administration (FDA) for moderate-to-severe plaque psoriasis in 2023. A PubMed search was performed using the keywords "bimekizumab," "plaque psoriasis," and "bimekizumab clinical tri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Annals of pharmacotherapy 2024-10, p.10600280241288553
Hauptverfasser:	Greer, Margaret E, Moran, Shannon K, Feldman, Steven R
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!